JPRN-UMIN000032849
Recruiting
未知
Multicenter phase I/II study of switching therapy from lenalidomide and dexamethasone to elotuzumab plus lenalidomide and dexamethasone for multiple myeloma patients not achieving deep response - Switching study from Rd to ERd for multiple myeloma (EAO-18 study)
orth Japan Hematology Study Group0 sites27 target enrollmentJune 8, 2018
Conditionsmultiple myeloma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- multiple myeloma
- Sponsor
- orth Japan Hematology Study Group
- Enrollment
- 27
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.Patients with HIV\-antibody positive 2\.Patients with synchronous or metachronous malignancy except carcinoma in situ or cancer confined to the mucosa and curatively treated by local resection 3\.Patients with active infectious disease 4\.Pregnant women, women who could be pregnant or women who is breast feeding 5\.Patients with history of hypersensitivity for the component of elotuzumab 6\.Patients with other inadequate conditions determined by investigators
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Study for efficacy and safety of switching treatment from ENBREL to etanercept biosimilarJPRN-UMIN000032633Matsubara Mayflower Hospital200
Active, not recruiting
Not Applicable
trial evaluating the efficacy of omalizumab (Xolair ®) in idiopathic refractory severe solar urticariaEUCTR2013-004910-16-FRCentre Hospitalier régional Universitaire de Besançon
Active, not recruiting
Phase 1
A multicenter Phase I/II trial investigating the safety and efficacy (CR rate and OS) of low dose AraC with Clofarabine in patients =60 years with AML not eligible for conventionalChemotherapyMedDRA - 10000886, akute myeloische Leukämie, acute myeloid leukemiaC92.0Acute myeloblastic leukaemia [AML]DRKS00000580niversität Leipzig13
Active, not recruiting
Not Applicable
A multicenter Phase I/II trial investigating the safety and efficacy (CR rate and OS) of low dose AraC with Clofarabine in patients =60 years with AML not eligible for conventionalChemotherapy - ClofarabineAcute myeloid leukaemiaMedDRA version: 12.1Level: PTClassification code 10000880Term: Acute myeloid leukaemiaMedDRA version: 12.1Level: LLTClassification code 10000880Term: Acute myeloid leukaemiaEUCTR2009-017347-33-DEniversity of Leipzig60
Active, not recruiting
Phase 2
WJOG11118JPRN-jRCTs041200046Hirotsugu Kenmotsu30